Annexin A1: the protein that makes immunity grow old ✎ bioRxiv

Original: "Transplanting ANXA1- CD8+ Naive T cells Delay Aging Through Senolysis"
b42w:2602.90006 · the paper's page · 2026-02-23 · CC BY-NC-ND 4.0 · independent analysis · 2 min
As we age, a special kind of T cell carrying the protein ANXA1 on its surface accumulates in the bone marrow. These cells lose their fighting ability and put the brakes on immunity, and clearing them out rejuvenates the body.

In the bone marrow, as in a barracks, there is a constant roll call. Rookie T cells wait for their first assignment, and for a while they all look alike. But with age, soldiers with a special mark on their uniform start to appear among them: the protein annexin A1. This mark is not a decoration but a brake shoe that keeps the cell from charging into battle.

Researchers peered into the bone marrow of 15 healthy donors aged 3 to 91 and watched how the makeup of this barracks changes. The main age-related shift is a shrinking share of naive CD8+ T cells, those very rookies. But among those that remain, more and more carry ANXA1. These cells keep their naive appearance, yet inside they are no longer fighters: their senescence markers are elevated, their activation and proliferation are reduced, and instead of a battle cry they release pro-inflammatory signals that poison those around them.

ANXA1+ cells are not just passive bystanders. They actively sustain aging by releasing SASP factors, molecular calls to inflammation.

To understand how this brake shoe works, the scientists turned to mice. In mice with a knockout of the Anxa1 gene, T cells activated more strongly, produced more interferon-gamma and destroyed melanoma cells more effectively. And when old mice received monthly transplants of CD8+ naive T cells without ANXA1, those cells selectively eliminated senescent cells throughout the body. The result: better physical performance, a rejuvenated immune profile in the bone marrow, and a median lifespan extended by more than 30 weeks.

For humans, this is equivalent to roughly 100 years of life. Mice that received cells without ANXA1 were twice as likely to live to 30 months.

The story comes full circle: the roll call in the barracks can become stricter if you strip the brake shoes off the uniforms. T cells without ANXA1 are not just young cells, but cells that have been given back the ability to restore order. Perhaps in the future, instead of cell transplants, drugs that block ANXA1 will appear, and then the body's own immune system will be able to clear out senescent cells on its own.

The median lifespan of mice receiving ANXA1- CD8+ naive T cells increased by more than 30 weeks, which translates to roughly 100 human years.

The idea of rejuvenation through transfusion of young immune cells echoes Aldous Huxley's novel Brave New World, where youth is maintained through hormone therapy, and the 2015 film The Immortals, where blood transfusions from young donors halt aging.

Take the whole work

Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.